The first study comparing the improvement in glucose metabolism following roux-en-y gastric bypass (RYGB) surgery to the less invasive endoscopic placement of a duodenojejunal bypass liner (DJBL, the EndoBarrier device) has found that although RYGB was superior by inducing weight loss, both procedures have a similar impact on diabetes remission, indicating that alteration of weight loss itself is not the main determinant of improvement in glucose homeostasis in these obesity procedures.

According to the company, the data show that EndoBarrier - specifically designed to mimic the duodenal-jejunal exclusion created by gastric bypass surgery - has a significant impact on glucose homeostasis at one, three and nine months of therapy, which can reduce the reliance patients may have on diabetes medications.

“It is interesting to observe how EndoBarrier treatment compares to bariatric surgery when administered at the same clinical center in the hands of independent researchers,” said Dr David Maggs, chief medical officer of GI Dynamics. “This is another important milestone that manifests the potential for device intervention while avoiding the alteration of anatomy by surgery.”

Want more stories like this? Subscribe to Bariatric News!

Bariatric News

Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.